BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 20856855)

  • 21. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
    Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N
    Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
    Fischer C; Leithner K; Wohlkoenig C; Quehenberger F; Bertsch A; Olschewski A; Olschewski H; Hrzenjak A
    Mol Cancer; 2015 Jan; 14():4. PubMed ID: 25608569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Shikonin induces apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1 signaling antagonized by p300.
    Jeung YJ; Kim HG; Ahn J; Lee HJ; Lee SB; Won M; Jung CR; Im JY; Kim BK; Park SK; Son MJ; Chung KS
    Biochim Biophys Acta; 2016 Nov; 1863(11):2584-2593. PubMed ID: 27452907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disruption of NADPH homeostasis by total flavonoids from Adinandra nitida Merr. ex Li leaves triggers ROS-dependent p53 activation leading to apoptosis in non-small cell lung cancer cells.
    Lan T; He S; Luo X; Pi Z; Lai W; Jiang C; Gan J; Wei S; Wu Z; Yun C; Leng J; Li C
    J Ethnopharmacol; 2024 Oct; 332():118340. PubMed ID: 38762212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation.
    Oh SH; Whang YM; Min HY; Han SH; Kang JH; Song KH; Glisson BS; Kim YH; Lee HY
    Int J Cancer; 2012 Nov; 131(10):2253-63. PubMed ID: 22362554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KiSS-1 Modulation by Epigenetic Agents Improves the Cisplatin Sensitivity of Lung Cancer Cells.
    Beretta GL; Alampi D; Corno C; Carenini N; Corna E; Perego P
    Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.
    Yang YT; Balch C; Kulp SK; Mand MR; Nephew KP; Chen CS
    Neoplasia; 2009 Jun; 11(6):552-63, 3 p following 563. PubMed ID: 19484144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
    Rundall BK; Denlinger CE; Jones DR
    Surgery; 2005 Aug; 138(2):360-7. PubMed ID: 16153448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.
    Chien CW; Yao JH; Chang SY; Lee PC; Lee TC
    Toxicol Appl Pharmacol; 2011 Nov; 257(1):59-66. PubMed ID: 21889949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
    Noro R; Miyanaga A; Minegishi Y; Okano T; Seike M; Soeno C; Kataoka K; Matsuda K; Yoshimura A; Gemma A
    Cancer Sci; 2010 Jun; 101(6):1424-30. PubMed ID: 20384633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells.
    Chun SM; Lee JY; Choi J; Lee JH; Hwang JJ; Kim CS; Suh YA; Jang SJ
    PLoS One; 2015; 10(3):e0119379. PubMed ID: 25781604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation.
    Bao L; Diao H; Dong N; Su X; Wang B; Mo Q; Yu H; Wang X; Chen C
    Cell Biol Toxicol; 2016 Dec; 32(6):469-482. PubMed ID: 27423454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.
    Adeegbe DO; Liu Y; Lizotte PH; Kamihara Y; Aref AR; Almonte C; Dries R; Li Y; Liu S; Wang X; Warner-Hatten T; Castrillon J; Yuan GC; Poudel-Neupane N; Zhang H; Guerriero JL; Han S; Awad MM; Barbie DA; Ritz J; Jones SS; Hammerman PS; Bradner J; Quayle SN; Wong KK
    Cancer Discov; 2017 Aug; 7(8):852-867. PubMed ID: 28408401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies.
    Huang WJ; Tang YA; Chen MY; Wang YJ; Hu FH; Wang TW; Chao SW; Chiu HW; Yeh YL; Chang HY; Juan HF; Lin P; Wang YC
    Cancer Lett; 2014 Apr; 346(1):84-93. PubMed ID: 24355296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
    You BR; Han BR; Park WH
    Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Flavonoids potentiated anticancer activity of cisplatin in non-small cell lung cancer cells in vitro by inhibiting histone deacetylases.
    Yan W; Wu THY; Leung SSY; To KKW
    Life Sci; 2020 Oct; 258():118211. PubMed ID: 32768576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of rapamycin and SAHA enhanced radiosensitization by inducing autophagy and acetylation in NSCLC.
    Wang Y; Liu F; Fang C; Xu L; Chen L; Xu Z; Chen J; Peng W; Fu B; Li Y
    Aging (Albany NY); 2021 Jul; 13(14):18223-18237. PubMed ID: 34321364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.
    Kato Y; Salumbides BC; Wang XF; Qian DZ; Williams S; Wei Y; Sanni TB; Atadja P; Pili R
    Mol Cancer Ther; 2007 Jan; 6(1):70-81. PubMed ID: 17237267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid.
    Greve G; Schiffmann I; Lübbert M
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2171-80. PubMed ID: 26008188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.